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Abstract
Background: It is widely accepted that neuroinflammatory processes play an important role in the pathogenesis
of Alzheimer’s disease (AD) and high levels of cytokines and chemokines are detected around Aβ plaques.
Methods: As neuroinflammation is involved in the development and progression of AD, we measured the
pro-inflammatory cytokines interleukin 1β (IL-1β), IL-8 and tumor necrosis factor α (TNF-α) in serum and
cerebrospinal fluid (CSF) samples from 45 AD patients and 53 age-matched control subjects using a highly
sensitive multiplex electrochemiluminescence assay. To address the association with disease progression we
correlated cognitive status with cytokine levels.
Results: CSF as well as serum IL-8 levels were found to be significantly lower in AD patients than in controls
(p = 0.02). A statistically significant inverse correlation was observed between the CSF level of IL-1β and the
MMSE score (rs = -0.03, p = 0.02). We therefore stratified the AD patients by their MMSE scores into three equal
groups and found that in the AD group with the most severe cognitive impairment CSF-IL-1β was significantly
increased compared to age-matched controls (p < 0.05), whereas in the other investigated groups the increase
was not statistically significant.
Conclusion: Our results confirm data suggesting that cytokine alterations are involved in AD pathogenesis and
may be helpful as a biomarker for monitoring disease progression.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder and the most common form of dementia
worldwide [1, 2]. The major neuropathological hallmarks
of the disease are (I) extracellular senile plaques mainly
composed of amyloid-β (Aβ) peptides, which are often
surrounded by reactive glia and dystrophic neurites, (II)
intracellular neurofibrillary tangles composed of hyper-
phosphorylated tau protein as well as (III) neuronal loss
and synaptic dysfunction [3–5].
A growing number of studies further implicated neuro-
inflammation in the pathogenesis of AD [6–8]. Reactive
microglia and astrocytes cluster around Aβ plaques both
in the brains of individuals with AD as well as in trans-
genic mice [9–12] and have been suggested to promote
neurodegeneration. Once activated by pathological trig-
gers such as neuronal death or protein aggregates, micro-
glia undergo a rapid change in morphology. They migrate
to the lesion initiating an innate immune response by
producing cytotoxic factors such as pro-inflammatory
cytokines, chemokines and reactive oxygen species. Since
neuroinflammation seems to play a role in neurodegenera-
tion, several studies have suggested that cytokines might
enhance this inflammatory process contributing to synap-
tic dysfunction and subsequent neuronal death. For ex-
ample, interleukin (IL)-1β can be detected in reactive
astrocytes surrounding Aβ deposits [13, 14] and Aβ was
shown to induce the production of IL-1β [15]. Levels of
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IL-1β were found to be elevated in cerebrospinal fluid
(CSF), plasma samples or post-mortem brain tissue of AD
patients [16–19], while other studies reported no changes
in IL-1β in serum or CSF of AD patients compared to
controls [20, 21].
Regarding AD, the above-mentioned IL-1β as well as
IL-6, IL-8, IL-10, IL-12, tumor necrosis factor (TNF)-α
and transforming growth factor (TGF)-β have been in-
tensively studied in post-mortem brain tissue, serum and
CSF samples (reviewed in [22–24]). Many of these stud-
ies, however, are limited by test cohort sample size and
methodological differences analyzing only post-mortem
brain tissue, serum or CSF. Furthermore, the results of
different studies are often inconsistent and correlations
between clinical variables such as mini-mental state exam-
ination (MMSE) and cytokine levels in AD patients are
often missing.
Currently, AD can be definitively diagnosed only after
death by post-mortem examination of the brain [25, 26].
Neurodegeneration in AD, however, is estimated to start
decades before the first clinical symptoms appear. Thus,
reliable biomarkers are needed for an early diagnosis of
the disease. As cytokines have already been shown to be
associated with AD, the aim of this study was to further
elucidate the role of cytokines in AD by simultaneous
assessment of IL-1β, IL-8 and TNF-α levels in serum and
CSF samples of AD patients compared with age-matched
controls and to investigate whether these cytokines correl-
ate with cognitive performance.
Methods
Patients
CSF and blood samples were collected at the Memory
Clinic of the Department of Neurology, University Hos-
pital Ulm, from 2003 to 2012. A total of 98 subjects were
included in this study: 45 AD patients and 53 age-matched
controls (Table 1). Paired CSF and serum samples were
collected from 31 AD patients and 21 age-matched con-
trols. Medical histories, as well as neurological, psychiatric,
neuroradiological and neuropsychological examinations
including MMSE, were obtained. AD patients were diag-
nosed according to the National Institute of Neurological
and Communicative Diseases and Stroke–Alzheimer's Dis-
ease and Related Disorders Association criteria [27] and
the DSM-IV-TR criteria [28]. Patients with AD showed
positive CSF biomarkers (Aβ42 < 550 pg/ml, total tau >
400 pg/ml), while controls displayed a negative biomarker
profile. The subgroups including the patients stratified by
MMSE were equal-sized.
The control group of patients did not show clinical
symptoms of dementia and underwent a lumbar puncture
for other differential diagnostic reasons excluding acute
or chronic inflammatory conditions. The final diagnoses
were as follows: depression (n = 5), subjective cognitive
impairment (n = 3), history of epilepsy (n = 2), neuropathic
pain syndrome (n = 2); one patient each had: aneurysm,
amblyacousia, myopathy, mild cognitive impairment, anx-
iety, cardiac insufficiency, gait abnormality, Tolosa-Hunt
syndrome, stroke.
Clinical examination of the study participants did not
show any signs of ongoing infection.
Sample collection
CSF sample collection was performed using a standard-
ized protocol as described previously [29]. Briefly, CSF
was obtained by lumbar puncture into polypropylene
tubes, to avoid possible adsorption of proteins to the tube
wall. Samples were centrifuged at 1000 x g for 10 min,
aliquoted and stored at -80 °C until analysis. CSF-Aβ42
and total tau protein levels were determined using com-
mercially available INNOTEST® β-amyloid (1-42) and hTau
Ag ELISA assay kits (Innogenetics, Gent, Belgium) accord-
ing to the manufacturer’s instructions.
Cytokine measurement
IL-1β, IL-8 and TNF-α were measured in CSF and
serum samples using human proinflammatory cytokine
assay kits and a SECTOR Imager S 6000 instrument
(Mesoscale Discovery, Rockville, MA, USA) according
to the manufacturer’s instructions. Samples were mea-
sured in duplicate. The assays were blind for patient
identification and disease status. The detection limits
were 0.28 pg/ml for IL1-β, 0.10 pg/ml for IL-8 and
0.29 pg/ml for TNF-α.
Table 1 Demographic and clinical characteristics of patients and controls included in this study
CSF donors database Serum donors database
AD (n = 41) Control (n = 23) AD (n = 36) Control (n = 24)
Age, y median (IQR) 68 (66–72) 69 (63–73) 68 (66–70) 70 (64–72)
Sex, f/m (% f/m) 29/12 (70.7) 13/10 (56.5) 25/11 (69.4) 12/12 (50.0)
MMSE, median (IQR) 21.5 (17.0–24.0)* 29.0 (n = 12) (28.0–30.0) 21.0 (17.0–23.5)* 29.0 (n = 14) (28.0–30.0)
CSF Aβ42 (pg/ml), median (IQR) 472.0 (367.0–569.0)* 1014.0 (n = 14) (875.8–1191.8) 476.0 (373.8–577.3)* 1014.0 (n = 14) (875.8–1191.8)
CSF T-tau (pg/ml), median (IQR) 616.0 (371.0–1009.0)* 228.0 (n = 14) (204.8–279.8) 659.0 (412.8–1129.0)* 228.0 (n = 14) (204.8–279.8)
Data are presented as median values and interquartile ranges (IQR). 31 AD patients as well as 21 controls donated both CSF and serum. p-values were calculated
using the Mann-Whitney test, AD vs. control *p < 0.0001
Hesse et al. BMC Neurology  (2016) 16:185 Page 2 of 8
Data analysis
The collected data failed a normality test (D'Agostino &
Pearson omnibus normality test) so the comparison of
groups was performed using the Mann-Whitney rank
sum test (two groups) or ANOVA on ranks (> two groups).
Spearman’s rank correlation analysis was used for cor-
relation analyses. p < 0.05 was considered statistically
significant and is indicated by an asterisk. n.s. indicates
non-significant differences. The results are expressed as
(median / 25th–75th percentile).
Results
Decreased IL-8 but not IL-1β or TNF-α levels in CSF of AD
patients
In our study cohort, the CSF IL-1β levels of AD patients
(0.54 / 0.27–0.82 pg/ml) showed no change compared
to non-demented elderly control subjects (0.33 / 0.24–
0.53 pg/ml; p = 0.12) (Fig. 1a). IL-8 levels were found to
be significantly lower in AD patients than in controls
(AD: 35.0 / 29.67–46.16 pg/ml, control: 41.73 / 36.73–
58.74 pg/ml; p = 0.02) (Fig. 1b). In the case of TNF-α,
its level in CSF was not changed in AD samples (0.42 /
0.30–0.64 pg/ml) compared to control subjects (0.51 /
0.29–0.70 pg/ml; p = 0.83) (Fig. 1c). As depression fre-
quently occurs already in early stages of AD and IL-8 is
discussed to be involved in depressive disorders, we
included subjects suffering from depression in our con-
trol cohort as well. We compared CSF IL-8 levels of
control subjects suffering from a depression (39.10 / 35.71–
54.84 pg/ml) with CSF IL-8 levels of non-depressed control
subjects (44.01 / 35.94–67.43 pg/ml). We did not see a sta-
tistically significant difference (p = 0.71) (Additional file 1:
Figure S1A). Further we omitted the depressed control
subjects (44.01 / 35.94–67.43 pg/ml) and compared
CSF IL-8 levels with these of AD patients (35.90 / 29.67–
46.16 pg/ml) and observed the same difference as when
the depressed control subjects were included (p = 0.03)
(Additional file 1: Figure S1C).
Decreased IL-8 but not IL-1β or TNF-α levels in serum of
AD patients
Serum IL-1β levels in AD patients (0.43 / 0.23–0.61 pg/ml)
showed no differences compared to control subjects (0.42 /
0.21–0.77 pg/ml; p = 0.81) (Fig. 2a). IL-8 levels, by com-
parison, were again found to be significantly lower in AD
patients than in controls (AD: 6.14 / 2.38–10.24 pg/ml,
control: 9.06 / 6.62–12.94 pg/ml; p = 0.02) (Fig. 2b). As in
CSF, TNF-α serum levels were not significantly altered in
AD samples (5.87 / 5.00–6.82 pg/ml) compared to elderly
controls (6.87 / 5.37–8.07 pg/ml; p = 0.05) (Fig. 2c). To
exclude depression as confounding variable in measure-
ment of cytokine levels in serum as well, we also com-
pared serum IL-8 levels of control subjects suffering
from depression (7.80 / 6.20–70.17 pg/ml) with serum
IL-8 levels of non-depressed control subjects (9.64 /
7.00–13.13 pg/ml). We did not see a statistically signifi-
cant difference (p = 0.31) (Additional file 1: Figure S1B).
Further we again omitted the depressed control subjects
(9.64 / 7.00 – 13.13 pg/ml) and compared serum IL-8
levels with these of AD patients (6.14 / 2.38–10.24 pg/ml)
and observed the same difference as when the depressed
control subjects were included (p = 0.02) (Additional file
1: Figure S1D). We concluded that in our cohort CSF as
well as serum IL-8 levels are not altered in patients suffer-
ing from a depression and decided to leave them included
in our cohort.
Correlations among CSF/serum markers and MMSE score
and neurodegeneration biomarkers
We examined the correlations between cytokine CSF and
serum levels in AD patients and their MMSE scores as
well CSF Aβ42 as and CSF total tau levels as
Fig. 1 Cytokine levels in CSF samples of AD patients compared to controls. Box plots comparing CSF IL-1β, IL-8 and TNF-α levels between AD
patients and age-matched controls. a IL-1β levels were not altered in AD patients compared to controls (p = 0.12). b IL-8 levels, by comparison,
were significantly reduced in AD patients (p = 0.02). c TNF-α showed no significant difference (p = 0.83). Dark horizontal lines represent the
mean, with the box representing the 25th and 75th percentiles of the observed data, the whiskers representing the 5th and 95th percentiles,
and outliers represented by dots. P values were calculated using the Mann-Whitney Rank sum test
Hesse et al. BMC Neurology  (2016) 16:185 Page 3 of 8
neurodegenerative markers. Only patients with complete
biomarker profiles, including CSF Aβ42, CSF total tau and
MMSE scores were included in correlation analysis.
CSF total tau and CSF Aβ42 showed no statistically sig-
nificant correlation with CSF IL-1β, CSF IL-8 or CSF
TNF-α levels (Table 2). However, we observed a trend
towards a correlation between CSF total tau and CSF
IL-8 levels (rs = 0.02, p = 0.06). A statistically significant
inverse correlation was observed between the CSF IL-
1β concentration and the MMSE score (rs = -0.03, p =
0.02). We therefore stratified the AD patient samples
by MMSE score into three equal-sized subgroups reflect-
ing very mild, mild and moderate clinical AD stages and
found that in the MMSE (11–18) group (moderate AD)
IL-1β was significantly increased compared to age-
matched controls (p < 0.05) (Fig. 3), while the mild MMSE
(≥24) and the mild to moderate MMSE (18–23) showed
no statistically significant difference.
There was no association between the CSF and serum
levels of the respective cytokines and also no association
between the analyzed cytokines. In addition, measurements
of albumin in the CSF and serum of AD and non-dementia
patients excluded the possibility that dysfunction of the
blood/CSF barrier influenced the level of cytokines in the
CSF in the current cohort of AD patients (data not shown).
To test the diagnostic power of cytokines for the dis-
crimination of AD patients and controls, ROC analysis was
performed. Cut-offs were calculated using Youden’s index
and likelihood ratio (Additional file 2: Table S1). CSF IL-8
(AUC: 0.68, 95 % CI: 0.54–0.81, p = 0.02) as well as serum
IL-8 (AUC: 0.68, 95 % CI: 0.54–0.82, p = 0.02) and CSF
IL1-β (AUC: 0.62, 95 % CI: 0.48–0.75, p = 0.12) showed
limited power and therefore do not show biomarker poten-
tial as single markers. The highest discrimination power
showed the ratio of CSF IL-1β and CSF IL-8 (AUC: 0.71,
95 % CI: 0.58-0.83, p = 0.01) (Additional file 3: Figure S2).
Fig. 2 Cytokine levels in serum of AD patients and age-matched controls. Box plots comparing Serum IL-1β, IL-8 and TNF-α levels between AD
patients and age-matched controls. a IL-1β levels were unchanged (p = 0.81). b IL-8 levels were significantly reduced in AD patients (p = 0.02).
c TNF-α showed a slight reduction in AD patients but the observed effect was not significant (p = 0.05). Dark horizontal lines represent the mean,
with the box representing the 25th and 75th percentiles of the observed data, the whiskers representing the 5th and 95th percentiles, and outliers
represented by dots. P values were calculated using the Mann-Whitney Rank sum test
Table 2 Correlations among CSF cytokine concentrations and
MMSE, Aβ and total tau protein
CSF IL-1β CSF IL-8 CSF TNF-α
rs p rs p rs p
MMSE −0.33 0.02 0.02 0.89 −0.03 0.86
Aβ42 −0.13 0.38 0.10 0.47 −0.03 0.86
Tau 0.22 0.12 0.26 0.06 −0.08 0.56
Correlation coefficient (rs) and p-values were calculated using Spearman’s rank
correlation analysis. Statistically significant results are depicted in bold
Fig. 3 Analysis of IL-1β levels in CSF of stratified patients by MMSE.
CSF IL-1β levels inversely correlated with MMSE score. To further
analyze this correlation, AD patients were grouped according to
their MMSE score and IL-1β levels were compared to age-matched
controls. Box plots represent median levels of CSF IL-1β with the box
representing the 25th and 75th percentiles of the observed data, the
whiskers showing the 5th and 95th percentiles and dots representing
outliers. The MMSE (11-18) group IL-1β was significantly increased
compared to the other investigated groups (p < 0.05, ANOVA on
Ranks, Dunn’s method)
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Discussion
Neuroinflammation is a common feature underlying the
development and progression of neurodegenerative dis-
orders including AD (reviewed in [30–32]). Microglia,
the resident innate immune cells within the central ner-
vous system, as well as astrocytes seem to play a central
role in promoting this process. When compared to con-
trols, brains from AD patients show increased numbers
of activated microglia clustering both in and around Aβ
plaques [4, 10]. Microglial activation results in the pro-
duction of pro-inflammatory cytokines such as IL-1β or
TNF-α, which contribute to the inflammatory reaction.
Several studies have analyzed the secretion of these cyto-
kines in the serum and CSF of AD patients (for review
see [22–24]). However, different study designs and types
of samples lead to conflicting results that make the use
of cytokines as biomarkers for AD impossible. In this
study, we analyzed IL-1β, IL-8 and TNF-α in CSF and
serum samples of AD patients using a highly sensitive
multiplex electrochemiluminescence assay and compared
the obtained concentrations with age-matched controls.
The pro-inflammatory cytokine IL-1β is believed to
drive the neuroinflammatory process and has been dem-
onstrated to be upregulated in AD and other neurode-
generative disorders [14, 18, 19]. However, there are also
studies reporting that both CSF and serum IL-1β levels
in AD patients are not altered [33]. In our study cohort
we did not see a significant difference in IL-1β levels in
CSF or serum in AD patients compared to age-matched
control subjects. Interestingly however, correlation ana-
lysis revealed that CSF IL-1β levels inversely correlated
with MMSE scores. We therefore split the AD group
into MMSE-tertiles and identified that with increasing
cognitive impairment IL-1β levels are significantly increased
compared with age-matched controls. The lowest MMSE
(11-18) group showed a 1.9 fold increase in CSF IL-1β,
compared with controls, while the other tested groups were
nearly unchanged. These results demonstrate that IL-1β
might be useful as a marker for the severity of the disease.
Further investigations in large cohorts are necessary to
confirm our findings.
IL-8, a microglia-derived chemokine inducing chemo-
taxis of cells to sites of injury [34], has also been implicated
in the pathogenesis of AD [35–37]. There are several
studies reporting an upregulation of IL-8 in AD pa-
tients [35, 38, 39], but reductions are demonstrated as
well [40–42]. In addition, a meta-analysis did not see
an association suggesting the involvement of IL-8 in
AD [23]. In our study cohort there was a significant reduc-
tion in CSF as well as serum IL-8 (CSF 0.84 fold, serum
0.68 fold). These conflicting results might be, at least in
part, explained by differences in the examined study popu-
lations. A study from 2003 performed by Galimberti and
colleagues does not provide characteristics of their study
cohort [35], while Alsadany et al. include a high propor-
tion of severe AD patients (50 % of the study cohort had
MMSE score <10) [38]. In the study cohort of Zhang et
al., the AD patients displayed very high total Tau levels
(1425.0 ± 104.3 pg/ml) [39]. These differences clearly dem-
onstrate the importance of standardized inclusion criteria.
Another study of Galimberti et al. from 2006 showed in-
creased CSF IL-8 levels in MCI as well as in AD patients
compared to non-demented controls, whereas these levels
decrease in AD patients compared to MCI patients. They
further observed a trend towards lower CSF IL-8 levels in
patients with MMSE scores <15 compared to patients with
MMSE scores ≥15 [43]. They argue that pro-inflammatory
events and intrathecal inflammation are more an initiation
factor and not a consequence of AD. The absolute CSF
IL-8 concentrations in our AD cohort and in the AD
cohort in their study were approximately the same. The
observed differences in CSF IL-8 concentrations could
therefore be explained by differences in control group
composition although patients with chronic or acute in-
flammatory conditions were excluded in both studies.
Supportive evidence for our findings comes from an in-
vitro study testing the effects of different chemokines
on hippocampal neuronal cultures. They could show that
IL-8 treatment promotes increased survival of neuronal
cultures, indicating trophic effects of this chemokine [44].
Decreased IL-8 levels in AD patients could therefore be as-
sociated with declined reparative mechanism in the CNS.
Interestingly, IL-8 has been shown to be involved in angio-
genesis [45], and upregulation of angiogenesis in AD is
hypothesized to promote neurodegeneration [46]. Whether
IL-8 is downregulated as a compensatory response to up-
regulated angiogenesis in AD requires further examination.
TNF-α is another pro-inflammatory cytokine that is fre-
quently reported to be regulated in AD (in any direction)
[33]. Brain-derived TNF-α is mostly produced by micro-
glia, astrocytes and neurons in response to pathological
stimuli. Secreted TNF-α in turn activates TNF-α produ-
cing cells in an autocrine manner, leading to further cyto-
kine production and astrogliosis [31]. Our measurement
of TNF-α in both CSF and serum samples of AD patients
and control subjects showed no significant differences be-
tween the two groups. Interestingly, studies reporting an
upregulation of TNF-α often analyzed patients with severe
AD, suggesting that the levels of this cytokine increase
gradually but continuously during disease progression
[33]. TNF-α is an unstable cytokine. For this reason, some
studies have evaluated TNF-α soluble receptors (sTNF-R1
and sTNF-R2), as indirect markers of TNF-α release [47].
Therefore determination of TNF-α receptor levels could
be helpful in understanding the involvement of TNF-α
regulation in AD progression.
In our study cohort there was no correlation between
the paired CSF and serum cytokine concentrations,
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indicating that the inflammatory environment in the
CSF is at least in part independent from systemic cyto-
kine production. This assumption is supported by the
fact that IL-8 levels in CSF are higher than in serum,
suggesting that IL-8 is more likely produced within the
brain than distributed via the blood stream.
Another important point in measurement of cytokine
levels is the cohort composition with regard to patient’s
co-morbidities. Co-morbidities like cancer or diabetes
are known to modulate inflammatory processes [48, 49].
Therefore we systematically excluded in our cohort pa-
tients suffering from these diseases. As IL-8 is discussed
to be associated with depressive disorders [50], we ana-
lyzed if control subjects in our cohort suffering from de-
pression confound CSF and serum IL-8 determination.
Therefore we compared CSF and serum IL-8 levels of
depressed control subjects with CSF and serum IL-8
levels of non-depressed control subjects. IL-8 levels of
the compared groups did not differ significantly. Fur-
ther we omitted the depressed control subjects and
compared CSF and serum IL-8 levels with these of AD
patients and observed approximately the same differ-
ence as when the depressed control subjects were in-
cluded. Therefore we decided to leave the depressed
control subjects included in our control cohort, as the
CSF as well as serum IL-8 levels were not altered in pa-
tients suffering from a depression. Since it has been shown
that ApoE as risk factor for AD suppress IL-1β and TNF-α
secretion in an isoform-specific manner, one has to be
aware the ApoE allel status when analyzing cytokines in
AD patients [51]. Unfortunately we did not determine the
ApoE status of all patients. Therefore we could not take
this parameter into account.
The clinical significance of these cytokine measurements
remains a subject of debate as the performed reported
studies display great discrepancies between them making
the use of inflammatory proteins as biological markers for
AD unfeasible. Different inclusion criteria, analyzed sample
sizes and the sensitivity of the assays used all contribute to
the reported variability. Several studies have analyzed cyto-
kine concentrations in the body fluid of AD patients with
commercially available ELISA kits. In some cases, however,
the cytokine levels were below the detection limit of the
respective ELISA assay leading to the exclusion of a large
proportion of the participants [17, 52, 53]. Furthermore,
the assays used, including ELISA and multiplex kits, are
quite heterogeneous leading to interassay variances. The
reliability of the measured cytokine concentrations could
further depend on sample handling and storage condi-
tions [54–56]. Skogstrand et al. have demonstrated that
the measurable concentrations of inflammatory markers
increased in serum and plasma on storage before analysis
and the longer the time of storage before centrifugation
the greater the differences between serum and plasma
[57]. It is therefore of importance to provide guidelines for
sample collection and storage as well as for the used as-
says to be used under standardized conditions thus mak-
ing the observed data more reliable.
As there was only a marginal correlation between CSF
cytokine and neurodegeneration markers, this might re-
flect that IL-8 and IL-1β are independent biomarkers
possibly indicating separate pathogenic mechanisms in-
volved in AD.
Conclusion
In conclusion, our results show significantly reduced
CSF and serum IL-8 levels in AD patients as well as an in-
verse correlation between IL-1β concentration and MMSE
score. To determine cytokine serum and CSF levels, we
used a highly sensitive multiplex electrochemilumines-
cence assay. However, it should be kept in mind that dif-
ferent studies have led to different results, which might be
due to several reasons including patient selection and
assay methods. Because of this heterogeneity, more studies
with validated assays in well-defined cohorts are needed
to identify inflammatory biomarkers of AD, which could
improve the accuracy of diagnosis in diagnostic panels
and might lead to the development of therapeutic strat-
egies for immune modulation.
Additional files
Additional file 1: Figure S1. IL-8 levels in CSF and serum of depression
patients compared to non-depressed subjects in control group. Box
plots comparing IL-8 levels between depressed control subjects and
non-depressed controls. (A) CSF IL-8 levels were not altered in depressed
control subjects compared to non-depressed controls (p = 0.71). (B) Serum
IL-8 levels were unchanged in control subjects suffering from depression
compared to non-depressed controls (p = 0.31). (C) CSF IL-8 levels were
significantly reduced in AD patients compared to controls, when depressed
control subjects were excluded. (p = 0.03). (D) Serum IL-8 levels were
significantly decreased in AD patients compared to controls, when
depressed control subjects were excluded. (p = 0.02). Dark horizontal
lines represent the mean, with the box representing the 25th and 75th
percentiles of the observed data, the whiskers representing the 5th
and 95th percentiles, and outliers represented by dots. P values were
calculated using the Mann-Whitney Rank sum test. (TIF 15013 kb)
Additional file 2: Table S1. Characteristics of chemokines for AD in
ROC analysis. Sensitivity is defined as the fraction of those with the disease
correctly identified as positive by the test. Specificity is defined as the
fraction of those without the disease correctly identified as negative by the
test. Youden’s index was calculated as follows: sensitivity + specificity – 1.
Likelihood ratio equals sensitivity/(1 – specificity). AUC: area under the
curve, CI: 95 % confidence interval. (DOCX 16 kb)
Additional file 3: Figure S2. ROC curve analysis. X-axis: specificity (false
positive rate), Y-axis: sensitivity (true positive rate), (A) CSF IL-8, AUC: 0.68,
CI: 0.54-0.81, p = 0.02 (B) serum IL-8, AUC: 0.68, CI: 0.54-0.82, p = 0.02
(C) CSF IL-1β, AUC: 0.62, CI: 0.48-0.76, p = 0.12 (D) ratio CSF IL-1β/CSF
IL-8, AUC: 0.71, CI: 0.58-0.83, p = 0.01. AUC: area under the curve, CI: 95 %
confidence interval. Further characteristics of ROC analysis are depicted in
Additional file 2: Table S1. (TIF 16619 kb)
Abbreviations
AD: Alzheimer’s disease; Aβ: Amyloid β; CSF: Cerebrospinal fluid; IL: Interleukin;
MMSE: Mini-mental state examination; TNF-α: Tumor necrosis factor α
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